Last reviewed · How we verify

NCT07338968: CoMpass

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

Not yet recruiting Last updated 14 January 2026
What this trial tests

trial testing Observational in Choroidal Melanoma in 100 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
15 August 2033
15 August 2033

Quick facts

Lead sponsorAura Biosciences
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment100
Start date1 February 2026
Primary completion15 August 2033
Estimated completion15 August 2033

Drugs / interventions tested

Conditions studied

Sponsor

Aura Biosciences — full company profile →

Who can join

18 and older, any sex, with Choroidal Melanoma or Indeterminate Lesions. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Observational

Trials testing the same drug.

Other recruiting trials for Choroidal Melanoma

Currently open trials in the same condition.

Other Aura Biosciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07338968.